Mektovi and Doxycycline drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mektovi (binimetinib) and Doxycycline (doxycycline hyclate). Common drug interactions include disease progression among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Mektovi and Doxycycline. It is created by eHealthMe based on reports of 45 people who take the same drugs from the FDA, and is updated regularly.

What is Mektovi?

Mektovi has active ingredients of binimetinib. eHealthMe is studying from 6,179 Mektovi users. Check the latest studies of Mektovi.

What is Doxycycline?

Doxycycline has active ingredients of doxycycline hyclate. It is often used in acne. eHealthMe is studying from 60,868 Doxycycline users. Check the latest studies of Doxycycline.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

45 people who take Mektovi and Doxycycline together, and have interactions are studied.

Mektovi and Doxycycline drug interactions.

What are the common drug interactions of Mektovi and Doxycycline, by gender? *:

female:

Disease progression
Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)
Pyrexia (fever)
Abdominal pain upper
Alopecia (absence of hair from areas of the body)
Chills (felling of cold)
Constipation
Eye swelling
Lip swelling

male:

Diarrhoea
Vision blurred
Disease progression
Photophobia (extreme sensitivity to light)
Productive cough
Rash
Spinal fracture (fracture in one of vertebrae)
Vomiting
Blood triglycerides increased
Fall

What are the common drug interactions of Mektovi and Doxycycline, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Blindness transient (sudden loss of vision)
Disease progression
Photophobia (extreme sensitivity to light)
Vision blurred

40-49:

Disease progression

50-59:

Fall
Disease progression

60+:

Diarrhoea
Blood triglycerides increased
Nausea (feeling of having an urge to vomit)
Neuropathy peripheral (surface nerve damage)
Productive cough
Pyrexia (fever)
Rash
Spinal fracture (fracture in one of vertebrae)
Vomiting
Neoplasm progression (growth of tumour)

What are the existing conditions these people have? *

Colon Cancer: 15 people, 33.33%
Malignant Melanoma (skin cancer rises from melancytes): 12 people, 26.67%
Metastasis (spreadable cancer to other organ from origin): 4 people, 8.89%
Rectal Cancer (cancer of rectum): 3 people, 6.67%
Pulmonary Congestion (congestion in the lungs): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Mektovi and Doxycycline?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously